Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome.
about
The Crystal Structure of Shiga Toxin Type 2 with Bound Disaccharide Guides the Design of a Heterobifunctional Toxin InhibitorPentraxins: structure, function, and role in inflammationinGeno--an integrated genome and ortholog viewer for improved genome to genome comparisonsInteractions of Shiga-like toxin with human peripheral blood monocytes.Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome.A rapid and sensitive method to measure the functional activity of Shiga toxins in human serumThe pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodellingLipopolysaccharide renders transgenic mice expressing human serum amyloid P component sensitive to Shiga toxin 2Shiga toxin binding to glycolipids and glycans.Mouse models of Escherichia coli O157:H7 infection and shiga toxin injectionReduction of bleomycin-induced pulmonary fibrosis by serum amyloid P.Mass Spectrometry-Based Method of Detecting and Distinguishing Type 1 and Type 2 Shiga-Like Toxins in Human SerumIn vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins.Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans.Mutation of the Enterohemorrhagic Escherichia coli Core LPS Biosynthesis Enzyme RfaD Confers Hypersusceptibility to Host Intestinal Innate Immunity In vivoThe bundlin pilin protein of enteropathogenic Escherichia coli is an N-acetyllactosamine-specific lectinShiga Toxin Mediated Neurologic Changes in Murine Model of Disease.Efflux transport of serum amyloid P component at the blood-brain barrier.Protection of human podocytes from shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P componentTargeting bacterial toxins.Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety?Protection against Shiga ToxinsGlycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2.The impact of fertilization on the chicken egg yolk plasma and granule proteome 24 hours post-lay at room temperature: capitalizing on high-pH/low-pH reverse phase chromatography in conjunction with tandem mass tag (TMT) technology.Soluble Toll-Like Receptor 4 Impairs the Interaction of Shiga Toxin 2a with Human Serum Amyloid P ComponentThe Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs
P2860
Q27680604-06249CC8-0DCD-496A-AC1D-798E87B0F091Q28676262-DA12A23A-AD15-4A1A-B783-A4A531B94001Q33261031-E3578A67-1F4D-4111-B210-ECE1F1AAC279Q33375578-1B2A5E76-8752-4F92-A6A8-1037343E1255Q33425759-1D5CCDF5-0272-4A68-84B7-41B0091B8EEEQ33427445-F3C98265-028A-4947-AEAA-06338A93C33AQ33632041-054CA2AD-44DE-4360-AF05-E4892AD9349DQ33952458-CE188F3B-AEF0-4BE8-BFBF-9D4BB6FD5C1BQ34163196-0E69ACA8-BFF6-43FE-B166-DF511CA529D0Q34497115-8079B524-1D05-4078-B8AC-7F09735DD041Q35787045-D3C1317E-DEEA-4E5E-875A-7463DCA2F6ECQ36401470-BE722B77-7E26-463F-9652-D2A3983F5E10Q36950791-A808A463-0CBC-4C09-B057-F0C79F2DE3DBQ37077633-1600B065-9419-4009-9464-66698F7E2164Q37170303-236762A6-5472-4DF4-AF98-8E65BDC47A7FQ37259649-0ECF16B9-A25B-41A8-B6BF-F26A859748B3Q37293251-903F2C96-82B7-448D-B3E7-42DF84CBCAF0Q37337462-1495DC6C-1833-41A2-A487-AB5AB3BA7BDEQ37713382-A7ADA4EB-2FCA-46CB-80C2-74431AC378B2Q37996325-D5CD12DA-C339-47E7-B60D-30D39B7B7146Q38019401-3A74C450-A7ED-4D23-B508-9FC951F5EE3BQ38022246-04546463-1C4E-4223-BCE1-F7F6E2F42ED6Q39122055-98995DD8-D452-44AE-B169-4CDD175B31D5Q39673895-08E1922E-80DF-41D7-8576-D6ED3DBA249AQ40837009-1260BF76-2E77-4BE0-AA34-3C2B06AFB987Q58723219-0A0659C7-40A4-4E1D-80DB-58E90E433E6DQ59127894-309BBE0C-B2C1-4844-855F-52EDBD71F484
P2860
Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Human serum amyloid P componen ...... for hemolytic-uremic syndrome.
@ast
Human serum amyloid P componen ...... for hemolytic-uremic syndrome.
@en
type
label
Human serum amyloid P componen ...... for hemolytic-uremic syndrome.
@ast
Human serum amyloid P componen ...... for hemolytic-uremic syndrome.
@en
prefLabel
Human serum amyloid P componen ...... for hemolytic-uremic syndrome.
@ast
Human serum amyloid P componen ...... for hemolytic-uremic syndrome.
@en
P2093
P356
P1476
Human serum amyloid P componen ...... for hemolytic-uremic syndrome.
@en
P2093
George L Mulvey
Glen D Armstrong
Glenys A Tennent
Henrik Chart
Melvyn C Kahan
Paola Marcato
Thomas P Griener
P304
P356
10.1086/501472
P407
P577
2006-03-13T00:00:00Z